Results 111 to 120 of about 65,998 (238)

Future direction of systemic therapy for advanced renal cell carcinoma: lessons from final and extended follow-up data from the CheckMate 9ER trial. [PDF]

Transl Androl Urol
Ishihara H.
europepmc   +1 more source

Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery

World Journal of Surgery, EarlyView.
Luís Santos Castro, Lorenzo Ferri
wiley   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with <i>PD-L1</i> amplification: a case report. [PDF]

Ther Adv Med Oncol
Kodama H, Masuishi T, Ishizuka Y, Sakakida T, Honda K, Narita Y, Taniguchi H, Kadowaki S, Ando M, Hosoda W, Muro K.   +10 more
europepmc   +1 more source

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis. [PDF]

Clinicoecon Outcomes Res
Li B, Yang J, Li J, Huang J, Li Z.
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery. [PDF]

Eur Urol Open Sci
Tazawa S, Shinohara M, Kawashima Y, Sekine Y, Narita S, Kobayashi S, Abe N, Narita T, Fujita N, Mikami J, Okamoto T, Yamamoto H, Numakura K, Sato S, Habuchi T, Ohyama C, Hatakeyama S.   +16 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Imaging strategies for follow-up during adjuvant nivolumab in esophageal cancer: A multicenter retrospective cohort study. [PDF]

PLoS One
Huizer TJ, Strijdhorst A, Beerepoot LV, van Berge Henegouwen MI, van Doorn L, Derks S, Wijnhoven BPL, Mostert B, van Laarhoven HWM.   +8 more
europepmc   +1 more source